Serum HCV core antigen level is a useful prediction marker of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin in patients with chronic hepatitis C

• Shakado Satoshi

• Tanaka Takashi

• Inomata Shinjiro

• Anan Akira

• Matsumoto Teruo

• Hanano Takayuki

• Ueda Syuichi

• Morihara Daisuke

• Nishizawa Shinya

• Takeyama Yasuaki

• Yokoyama Masanori

• Irie Makoto

• Iwata Kaoru

• Sohda Tetsuro

• Sakisaka Shotaro

Bibliographic Information

Other Title

• Ｃ型慢性肝炎に対するペグインターフェロン，リバビリン併用療法２４週時の血清ＨＣＶ　ＲＮＡ陰性予測におけるコア抗原の有用性

Abstract

We analyzed prediction markers of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin for patients with chronic hepatitis C in Japan. Serum level of a pre-treatment HCV core antigen was significantly lower in patients negative for HCV RNA than in patients positive for HCV RNA at 24-week-treatment (p<0.01). The patients with a pre-treatment HCV core antigen level lower than 15000fmol/L and HCV core antigen loss (<20fmol/L) after one-month-treatment showed significantly higher negativity in serum HCV RNA at 24-week-treatment (p<0.05 and p<0.02, respectively). These date strongly suggest that the pre-treatment HCV core antigen level as well as HCV core antigen loss after one-month-treatment are useful prediction markers in efficacy of the combination therapy with peginterferon and ribavirin.<br>

Journal

• Kanzo

  Kanzo 47 (8), 411-412, 2006

  The Japan Society of Hepatology

Keywords

• chronic hepatitis C
• peginterferon
• ribavirin

Details

• CRID: 1390001204789053312
• NII Article ID: 10018264617
• NII Book ID: AN00047770
• DOI: 10.2957/kanzo.47.411
• ISSN: 18813593
• ISSN: 04514203
• Web Site: http://www.jstage.jst.go.jp/article/kanzo/47/8/47_8_411/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006304914
• Text Lang: ja
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed